Even if they make it possible to limit the serious forms of the disease, vaccines against Covid-19 do not prevent the transmission of the virus between people. When will we finally be able to abandon barrier gestures? A new French vaccine would seem capable of meeting this challenge! In addition, its mode of administration is original: it is a nasal spray.
Afrom the University of Tours an innovative project. It is a vaccine against SARS-CoV-2 which would block any contagiousness. In the current context, where new and ever more contagious variants appear regularly, could this project finally signal the end of masks? The French company LoValTech (for Loire Valley Technology), created in January 2022, holds the exclusive license to use the patent relating to the new vaccine. A is planned for the end of 2023, beginning of 2024.
A nasal vaccine suppressing contagiousness
Preclinical tests have been carried out in the laboratory on(hamster and mouse). The vaccination schedule is as follows: two nasal instillations spaced three weeks apart. The vaccine can trigger a but also to neutralize the . This is its originality: it would make it possible to suppress the transmission of the virus between people. The advantage is twofold. First, the virus stops spreading and infecting other people. Second, the virus circulates little and the risk of seeing new variants arise decreases. The in humans should start in the second quarter of 2022.
A vaccine effective against all variants?
The vaccine consists of non-mutating viral proteins. Which means the vaccine would be a priori effective against all variants of! How is it possible ? This vaccine triggers a cellular type and not only humoral. Where other vaccines stimulate the production of (humoral immunity), it also activates the (cellular immunity). The latest trials show that the vaccine is effective against of the coronavirus. Concerning , the research team is not yet in a position to say, but the preliminary results are encouraging.
And these are not the only advantages of this new kind of vaccine! This is made up of viral proteins and does not rely on mRNA technologies. Will it convince? It is also easy to store: between 4 and 20°C.
Even if there is no doubt that a large part of the European population will have received their three doses of vaccine when it is released, the fact remains that this nasal vaccine could constitute a major new tool to combat the virus in the countries.